Terrestrial

United States - Woburn, Massachusetts

• 27/03/2026
• Series C
• $50,000,000

Terrestrial is transforming the delivery of next-generation therapies, starting with GLP-1.

Terrestrial’s proprietary microarray patch (MAP) and applicator platform consists of a patch resembling an adhesive bandage, which is applied with a preloaded applicator and removed after a few minutes. Once applied, each patch delivers bioactive tips into the skin, which dissolve quickly into the body, rapidly releasing their therapeutic payload. Designed for self-administration, the temperature-stable MAP platform enables precise, controlled delivery of a wide range of therapeutics without medical sharps or refrigeration.

Terrestrial has generated strong clinical and in-vivo proof of concept across multiple molecules. For more information, visit www.terrestrialbio.com

Related People

Rachel ShaFounder

United States - Lexington, Massachusetts

The potential for digital to transform life sciences and healthcare is enormous, and my mission is to do this in a people-first way, at scale, and top speed. I am passionate about driving how we discover, develop, and bring innovative therapies and solutions to patients. As an entrepreneurial leader, I have extensive experience in this space, developing strategy, new business models, and products to ensure success.

I am experienced in negotiations and guiding complex transactions, alliance management, and company formation. As a strategic and collaborative leader, I have a record of building diverse teams that are recognized internally and externally as high-performing and high-potential.

LinkedIn https://www.linkedin.com/in/rachelsha/